Badger Meter (BMI) is a $3.3B water metering manufacturer — AMI hardware, BEACON SaaS, SmartCover sewer monitoring. Company guided FY2026 "relatively flat vs 2025" on April 17, a material downgrade from "high-single-digit" long-term framing. Stock fell another 30% the week of the guide and sits at a 52-week low. The April 20 10-Q surfaced three disclosures the 8-K didn't carry, and cross-ticker work on ROP, XYL, ITRI, and MWA shows BMI's narrative differs from every direct peer along three specific axes. ITRI's April 28 Q1 earnings disambiguate: sector digestion or BMI-specific.

What the filing says

Q1 2026 revenue $202.3M (-9.0% YoY). Utility Water -10.4%. Gross margin 41.7% vs 42.9% prior year. Diluted EPS $0.93 (-28.5%). Cash $205.5M, zero debt. Operating cash flow $33.9M (flat YoY despite the earnings decline; offset by payables surge).

Three items the 10-Q disclosed that the April 17 8-K did not:

  • UDlive acquisition $100M + earnout (Note 8 Subsequent Events). Management calls the deal "not expected to have a material impact" — implying UDlive revenue is sub-$10M. That's a premium for a UK sewer monitoring platform.
  • Buyback authorization doubled to $150M in February 2026 — after the Q4 guide-down. $38.2M deployed in Q1 at average $147.70/share; $114.7M remaining (≈3% of float at current prices).
  • Raw material inventory +$15.3M QoQ; finished goods +$1.9M only. Demand weakness accumulates as finished goods. BMI's composition is pre-buy behavior, not demand collapse.

Management attributed gross margin compression to "lower sales volume and less favorable product mix" — not copper or tariffs. Prior quarters emphasized input costs. SaaS revenue (recognized over time) grew 22% YoY to $24.7M (12.2% of revenue from 9.1%). International grew 17% YoY (Europe +22%, Asia +35%) while US declined 12%. CEO and an officer bought $754K of stock in February at $145-150.

PRASA — the 1.6M-connection Puerto Rico project that underpins the H2 2026 recovery narrative — is not mentioned anywhere in the 10-Q body.

What the market thinks

Price $113.17 at 52-week low (1% of range). Analyst targets range $110-197 (mean $162.50). On the April 20 print alone, four firms split four ways: RBC $169 Outperform, Barclays $110 Underweight, Stifel $140 Buy, Baird $145 Outperform. The sell-side cannot agree.

Options skew is one-sided: P/C 0.18 — crowd positioned long for a bounce. Max pain $125 (+10.5%). IV 40.8% at 41st percentile — priced for noise, not event. Short interest 14.4%; days to cover 7.8.

Idiosyncratic variance jumped to 92% after the post-guide selloff — above the 75% threshold for a standalone idiosyncratic bet — but the market is treating BMI as damaged goods inside a sector trough.

Why the gap exists

Cross-corpus work across ROP, XYL, ITRI, MWA transcripts from October 2025 through April 2026 shows BMI is uniquely situated on three axes:

  1. Margin attribution. ROP (Neptune) attributed margin pressure to copper and tariff surcharges "largely bucket... evaded Q4." MWA's Q1 10-Q explicitly cites tariffs. XYL blames inflation and volume. Only BMI rotated from copper/tariff framing (prior quarters) to "volume and mix." When management rotates from "commodity transient" to "volume persistent" while peers rotate the other way, that is often an early share-loss tell.
  2. Inventory. ITRI drew total inventory DOWN $27.8M YoY. XYL drew raw materials DOWN $14M. MWA built both, consistent with a raised guide. BMI's raw-material-only build is differentiated.
  3. Language. "Customer short cycle order pacing" is BMI's wording. Zero matches for "pacing" across ROP/XYL/ITRI transcripts in the same window. Peers use "backlog normalization," "project timing," "lumpy pace" — all one-cycle-resolvable. "Pacing" connotes persistent.

The market has collapsed BMI into a generic "water metering cycle digestion" read. The cross-ticker evidence argues the pattern is BMI-specific.

Risks

  • Squeeze. 14.4% short interest, 7.8 DTC, insider buys, buyback doubled, crowd P/C 0.18 — BMI is primed to pop on PRASA disclosure, UDlive close, or tariff refund quantification. Momentum crash risk applies: deeply negative-momentum names rally hardest when distress conditions reverse.
  • ITRI miss (28% base rate). ITRI reports Q1 on April 28. Four consecutive beats (+15%, +22%, +4%, +12%). But CFO sold $339K in February; IV sits at the 82nd percentile. If ITRI acknowledges short-cycle weakness, the sector factor is confirmed and BMI's read flips from share-loser to first-to-admit.
  • PRASA timeline slips. Absence of PRASA mention in the 10-Q is a yellow flag. A Q2 call that pushes PRASA to 2027 puts the "flat FY2026" guide at risk of further cuts.
  • Momentum mean-reversion. BMI RSI 25 at 52-week low. ITRI RSI 78 near recent highs. Both legs at technical extremes before any catalyst fires.

Catalysts

  • Apr 28 — ITRI Q1 2026 earnings. Primary disambiguation. Does Water Solutions segment language match BMI or the other peers?
  • Apr 30 — UDlive acquisition closes. Cash funded.
  • Late July — BMI Q2 2026 earnings. Share-loss test: does Utility Water decline YoY while ITRI Water Solutions grows?
  • By July 31 — PRASA deployment disclosure expected (tracked as a prediction).
  • Through Nov 2028 — Buyback authorization remaining $114.7M.

What would change our mind

  • ITRI cites short-cycle or replacement-order weakness in Water Solutions segment on Apr 28 → sector factor confirmed → BMI is first-to-admit, not share-loser.
  • BMI Q2 transcript shifts from "pacing" to "normalization" or "project timing" → language convergence with peers → share-loss hypothesis weakens.
  • PRASA 8-K lands before July 31 with specific deployment dates → load-bearing assumption de-risked.
  • ROP or XYL Q2 transcripts adopt "pacing" or "volume/mix" framing → BMI was first to say it, not the only one → sector factor.
  • BMI Q2 earnings print Utility Water growing YoY and SaaS above 14% of revenue — growth story reasserts.

Evidence

EvidenceSourceCredibilityLR
Q1 revenue -9% YoY ($202.3M); Utility Water -10.4%; EPS $0.93 (-28.5%)BMI 10-Q 2026-03-31, Consolidated Statements of Operations0.950.5
FY2026 guide "relatively flat vs 2025"BMI 8-K 2026-04-17, Item 2.020.950.5
UDlive acquisition $100M + 24-month EBITDA earnoutBMI 10-Q Note 8 Subsequent Events0.951.2
Buyback authorization doubled to $150M Feb 2026; $114.7M remaining; Q1 avg price $147.70BMI 10-Q Stockholders Equity Note0.951.5
Raw materials inventory +$15.3M QoQ; finished goods +$1.9MBMI 10-Q Note 4 Inventories0.951.3
GM compression attributed to "lower sales volume and less favorable product mix"BMI 10-Q MD&A0.951.3
SaaS (over-time) revenue +21.7% YoY to $24.7M; 12.2% of revenueBMI 10-Q Revenue Disaggregation0.951.4
International revenue +16.8% YoY (Europe +21.6%, Asia +35.1%, ME +29.6%)BMI 10-Q Revenue by Geography0.951.3
SCOTUS Feb 2026 ruling creates tariff refund opportunity; BMI "reviewing"BMI 10-Q MD&A0.951.2
"Customer short cycle order pacing" — zero matches across ROP/XYL/ITRI transcripts Oct 2025 - Apr 2026BMI 10-Q MD&A + cross-corpus transcript search0.901.6
ROP Q3-Q4 2025: Neptune softness = copper/tariff surcharges "now normalizing"ROP Q3 + Q4 2025 earnings transcripts0.901.5
ITRI Q4 2025: "bookings much more normalized pace, lumpy always lumpy"; pipeline +27%; Outcomes backlog +58%ITRI Q4 2025 earnings transcript0.901.2
ITRI drew total inventory DOWN $27.8M YoY; XYL drew raw materials DOWN $14M YoY; MWA built bothITRI/XYL/MWA most recent 10-Q filings0.951.4
MWA raised FY2026 guidance by $20M midpoint; "healthy municipal replacement activity"MWA Q1 2026 earnings release + call0.901.3
CEO + officer bought $754K BMI stock Feb 2026 at ≈$145-150Form 4 2026-02-09, 2026-02-100.951.1
PRASA not mentioned in 10-Q bodyBMI 10-Q 2026-03-31 (absence)0.950.8
Management incentive costs DOWN in Q1BMI 10-Q MD&A SEA bridge0.950.9

Net read: management actions convergently bullish, language uniquely pessimistic versus peers, market pricing a damaged-name read that cross-ticker evidence suggests is specific rather than structural. The disambiguation resolves at ITRI Q1 earnings on April 28.